Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neurothera LabsFRA:C0A +0.34%32 OCF Yield % is -0.27 as of Aug. 12, 2026. GuruFocus rates FRA:C0A with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Neurothera Labs ranks worse than 71.84% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Neurothera Labs OCF Yield % Related Terms
Neurothera Labs OCF Yield % Historical Data
* Premium members only.
The historical data trend for Neurothera Labs's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Neurothera Labs's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurothera Labs OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurothera Labs's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Neurothera Labs's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurothera Labs (FRA:C0A) has a OCF Yield % of -0.27 as of Aug. 12, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Neurothera Labs and its competitors. According to the industry distribution chart, Neurothera Labs ranks #722 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 71.8%.
Is Neurothera Labs' OCF Yield % too high?
Neurothera Labs' current OCF Yield % is -0.27. Based on the distribution chart, Neurothera Labs ranks #722 out of 1005 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Neurothera Labs has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Neurothera Labs' OCF Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Neurothera Labs ranks #722 out of 1005 companies for OCF Yield %. This places Neurothera Labs in the lower half of its industry. The industry median OCF Yield % is 3.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.40, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Neurothera Labs and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurothera Labs's current OCF Yield % is -0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurothera Labs stock overvalued right now?
Neurothera Labs (FRA:C0A) has a current OCF Yield % of -0.27. The current OCF Yield % is -0.27. Neurothera Labs' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Neurothera Labs (FRA:C0A), the current OCF Yield % is -0.27 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address325 Front Street West, 2nd Floor, Toronto, ON, CAN, M5V2Y1
Neurothera Labs Inc is a specialty clinical-stage pharmaceutical company. The company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With this focus, it has been engaged in developing and testing pharmaceutical compositions comprised of N-acylethanolamines, CBD and/or other cannabinoid receptors agonists. The Company is currently engaged in development programs based on tetrahydrocannabinol and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder and Status Epilepticus.
32GF Score
Get the complete analysis for FRA:C0A
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C0A has been successfully added to your 
